Commit Biologics ("Commit"), a pioneer in the activation of the complement system to treat autoimmune disease and cancer, today announces ...

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a strict and lifelong gluten-free diet is currently the only treatment.

Fintel reports that on December 12, 2024, Guggenheim downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Buy to Neutral. Analyst Price Forecast Suggests 1,981.80% Upside As of December 3 ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Q32 Bio Inc. (QTTB) on Thursday reported a loss of $11 million in its first quarter. On a per-share basis, the Waltham, Massachusetts-based company ...

WALTHAM, Mass., April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA ...

Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) has been assigned an average recommendation of “Hold” from the eight research firms that are currently covering the company, Marketbeat.com reports.

May 8, 2025 /PRNewswire/ -- Q32 Bio Inc. (QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and ...

Q32 Bio (NASDAQ:QTTB – Get Free Report) is expected to be releasing its earnings data before the market opens on Tuesday, March 11th. Analysts expect Q32 Bio to post earnings of ($1.25 ...

Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t ...

WALTHAM, Mass., Feb. 4, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune ...

Q32 Bio, Inc. (NASDAQ:QTTB), a biotechnology company focused on developing therapies for inflammatory diseases, has recently experienced significant shifts in its market outlook following ...